Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Partha Ray

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Annals of the American Thoracic Society|August 22, 2024
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2, Open-Label Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Annals of the American Thoracic Society|March 21, 2023
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2 Placebo-controlled Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Viruses|December 23, 2022
In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-ProteinBruna Andersen Pereira de Jesus, Anderson Albino Gomes, Alex E Clark, et al.
Human Mutation|April 23, 2013
ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutationAnna Sarkozy, Debbie Hicks, Judith Hudson, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Annals of the American Thoracic Society|August 22, 2024
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2, Open-Label Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Annals of the American Thoracic Society|March 21, 2023
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2 Placebo-controlled Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Viruses|December 23, 2022
In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-ProteinBruna Andersen Pereira de Jesus, Anderson Albino Gomes, Alex E Clark, et al.
Human Mutation|April 23, 2013
ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutationAnna Sarkozy, Debbie Hicks, Judith Hudson, et al.
Pageof 7